Granite Bio focuses on developing innovative therapies that leverage advanced genetic engineering techniques to address unmet medical needs. The company employs a proprietary platform that utilizes engineered proteins and gene editing technologies to create targeted treatments for various diseases. This approach allows for precise modifications at the genetic level, enabling the development of therapies that can effectively target specific biological pathways involved in disease progression.

In addition to its gene editing capabilities, Granite Bio is committed to advancing its pipeline of product candidates through rigorous scientific research and clinical development. The company emphasizes a strong foundation in molecular biology and biochemistry, which underpins its efforts to create novel therapeutics. By integrating cutting-edge technologies with a deep understanding of disease mechanisms, Granite Bio aims to deliver transformative solutions that improve patient outcomes and enhance the quality of life for individuals suffering from complex health conditions.

Switzerland

Granite Bio is a biotechnology company developing first-in-class antibodies that target the root causes of a variety of inflammatory, autoimmune and fibrotic conditions. Granite is backed by leading healthcare venture firms including Versant Ventures, Novartis Venture Fund, Forbion and Sanofi Ventures. 

Granite Bio

Company Details